Now that the UK’s new voluntary scheme on pricing, access and growth (VPAG) has been formally published, the British Generic Manufacturers Association has offered a slightly warmer response than it offered when details of the new scheme were first revealed.
BGMA Warms Up To UK’s VPAG Scheme
After Formal Publication Of New Voluntary Pricing Scheme That Includes Tiered Approach
Responding to the formal publication of the UK’s new voluntary scheme on pricing, access and growth, off-patent industry association the BGMA has praised the scheme’s new differentiated approach.
More from Regulation
• By
Echoing wider sentiments in the biosimilar and generic drug industry, the IGBA has warned of the potential consequences of mercantilist tariffs on the global drug supply and their impact on industry and patients.
• By
Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).
• By
As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.
• By
Complaints from UK originator association the ABPI over rising payments required by the country’s voluntary scheme for branded medicines pricing have been denounced by the BGMA, which says the differentiated scheme is “delivering precisely as it was intended.”
More from Policy & Regulation
• By
Complaints from UK originator association the ABPI over rising payments required by the country’s voluntary scheme for branded medicines pricing have been denounced by the BGMA, which says the differentiated scheme is “delivering precisely as it was intended.”
• By
The FDA generic drugs team’s first public workshop of the second Trump Administration ended with a request that industry amplify the value it finds from public engagement.
• By
Generics Bulletin reviews global regulatory developments across the globe.